山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (7): 13-20.doi: 10.6040/j.issn.1671-7554.0.2019.208
• • 上一篇
吴德沛1,2,陈晓晨1,2
WU Depei1,2, CHEN Xiaochen1,2
摘要： 淋巴瘤是最常见的血液系统恶性肿瘤之一,其亚型众多,具有高度异质性。既往淋巴瘤的治疗多采取化疗、放疗及手术在内的常规方法,但难治/复发一直是临床面临的棘手问题。近年来,免疫治疗的突破性进展给淋巴瘤患者带来新的希望。综述了近年来靶向淋巴细胞分化抗原的单克隆抗体及耦联药物,免疫检查点阻断剂及嵌合抗原受体T细胞等多种免疫治疗方法在淋巴瘤中的应用现状及未来展望。
中图分类号:
| [1] Minard CV, Brugieres L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead [J]. J Clin Oncol, 2015, 33(27): 2963-2974. [2] Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma [J]. J Clin Oncol, 2014, 32(9): 912-918. [3] Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101(obinutuzumab)compared with rituximab and ofatumumab in vitro and in xenograft models [J]. Mol Cancer Ther, 2013, 12(10): 2031-2042. [4] Barth MJ, Chu Y, Hanley PJ, et al. Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma [J]. Br J Haematol, 2016, 173(4): 597-616. [5] Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab(GA101)monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study [J]. J Clin Oncol, 2013, 31(23): 2912-2919. [6] Barth MJ, Hochberg J, Harrison L, et al. Phase 2 trial of obinutuzumab, a humanized glycoengineered monoclonal CD20 antibody, in combination with ifosfamide, carboplatin and etoposide for relapsed/refractory mature B-cell non-Hodgkin lymphoma [J]. Br J Haematol, 2018,182(Suppl 1): 48. [7] Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin(SGN-35)for relapsed CD30-positive lymphomas [J]. N Engl J Med, 2010, 363(19): 1812-1821. [8] Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression(AETHERA): a randomised, doubleblind, placebo-controlled, phase 3 trial [J]. Lancet, 2015, 385(9980): 1853-1862. [9] Locatelli F, Mauz KC, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkins lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study [J]. Lancet Haematol, 2018, 5(10): 450-461. [10] Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkins lymphoma AHOD1221): a Childrens Oncology Group, multicentre single-arm, phase 1-2 trial [J]. Lancet Oncol, 2018, 19(9): 1229-1238. [11] Metzger ML, Flerlage JE, Krasin M, et al. Safety and early response to the first 2 cycles of Brentuximab vedotin substituting vincristine in the OEPA/COPDAC regimen for high risk pediatric Hodgkin lymphoma(HL)[J]. Hema Sphere, 2018, 2(7): 36. [12] Kantarjian H, Jabbour E. Incorporating immunotherapy into the treatment strategies of B-cell adult acute lymphoblastic leukemia: the role of Blinatumomab and Inotuzumab Ozogamicin [J]. Am Soc Clin Oncol Educ Book, 2018, 38: 574-578. doi: 10.1200/EDBK_199505. [13] Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective [J]. Pharmacol Ther, 2012, 136(3): 334-342. [14] Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies [J]. Blood, 2018, 131(1): 30-38. [15] Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager(BiTE)Antibody construct blinatumomab for the treatment of patients with Relapsed/Refractory non-Hodgkin lymphoma: final results from a phase I study [J]. J Clin Oncol, 2016, 34(10): 1104-1111. [16] Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager(BiTE)antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma [J]. Blood, 2016, 127(11): 1410-1416. [17] Awashti A, Edani D, Azmy C, et al. Blinatumomab significantly enhanced cytotoxicity and T-cell cytokine secretion against Burkitt lymphoma(BL)and primary mediastinal B-cell lymphoma(PMBL)[J]. Br J Haematol, 2016, 182(8): 67-75. [18] Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies [J]. Blood, 2018, 131(1): 30-38. [19] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy [J]. Nat Rev Cancer, 2012, 12(4): 252-264. [20] Ilcus C, Bagacean C, Tempescul A, et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies [J]. Onco Targets Ther, 2017, 10(6): 2349-2363. [21] Dada R. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review [J]. Ann Hematol, 2018, 97(4): 555-561. [22] Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma [J]. N Engl J Med, 2015, 372(4): 311-319. [23] Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkins lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial [J]. Lancet Oncol, 2016, 17(9): 1283-1294. [24] Kasamon YL, De Claro RA, Wang YP, et al. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma [J]. Oncologist, 2017, 22(2): 585-591. [25] Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory Bcell non-Hodgkin lymphoma [J]. Clin Cancer Res, 2009, 15(20): 6446-6453. [26] Zinzani P, Ribrag V, Moskowitz CH, et al. Phase 1B study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-Cell lymphoma(rrPMBCL): updated results from the keynote-013 trial [J]. Hematol Oncol, 2017, 35(2): 189-190. [27] Zinzani P, Thieblemont C, Melnichenko V, et al. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-Cell Lymphoma(rrPMBCL): updated analysis of the keynote-170 phase 2 trial [J]. Hematol Oncol, 2017, 35(S2): 62-63. [28] Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study [J]. J Clin Oncol, 2016, 34(23): 2698-2704. [29] Ansell S, Gutierrez ME, Shipp MA, et al. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies(CheckMate 039)[J]. Blood, 2016, 128(2): 183. [30] Nastoupil LJ, Westin JR, Fowler NH, et al. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study [J]. J Clin Oncol, 2017, 35(12): 7519. [31] Younes A, Burke JM, Diefenbach CS, et al. Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: an interim analysis [J]. Hematol Oncol, 2017, 35. [32] Savoldo B, Ramos CA, Liu EL, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients [J]. J Clin Invest, 2011, 121(5): 1822-1826. [33] Chen LP, Flies DB. Molecular mechanisms of T cell costimulation and co-inhibition [J]. Nat Rev Immunol, 2013, 13(4): 227-242. [34] Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors [J]. Nat Med, 2015, 21(6): 581-590. [35] Kawalekar OU, OConnor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells [J]. Immunity, 2016, 44(2): 380-390. [36] Zhao ZG, Condomines M, Van DS, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells [J]. Cancer Cell, 2015, 28(4): 415-428. [37] Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-Cell lymphoma [J]. Blood, 2017, 130(2): 577. [38] Locke f, Neelapu S, Bartlett N, et al. Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel(axicel; KTE-C19)in patients with refractory aggressive non-Hodgkin lymphoma(NHL)[J]. AACR Annual Meeting, 2017, 77. doi:10.1158/1538-7445. |
| [1] | 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82. |
| [2] | 孙晨曦, 王永静, 李爱, 宋宁霞, 陈慧娴, 冯晓丽, 邓玉鹏, 王涓冬, 郑成云. 1例罕见成年XLP-1病例报道[J]. 山东大学学报 (医学版), 2022, 60(3): 117-120. |
| [3] | 于金明,颜薇薇,陈大卫. 肺癌放射免疫新实践[J]. 山东大学学报 (医学版), 2021, 59(9): 1-8. |
| [4] | 邓晓惠,郭玲. 免疫治疗在胚胎反复种植失败中的应用进展[J]. 山东大学学报 (医学版), 2021, 59(8): 32-37. |
| [5] | 庞兆飞,柳勇,赵小刚,闫涛,陈效伟,杜贾军. 基于公共数据库构建肺腺癌肿瘤干性评分模型预测免疫治疗疗效[J]. 山东大学学报 (医学版), 2021, 59(11): 19-28. |
| [6] | 李刚,薛皓,邱伟,赵荣荣. 脑胶质瘤抑制性免疫微环境形成机制及研究进展[J]. 山东大学学报 (医学版), 2020, 1(8): 67-73. |
| [7] | 黄晓军. 细胞免疫治疗在血液系统恶性肿瘤的应用进展[J]. 山东大学学报 (医学版), 2019, 57(7): 1-5. |
| [8] | 谢炜星,丁金勇,陈伟健,任东成,晋大祥. 腰椎管狭窄症合并左骶髂关节弥漫性大B细胞淋巴瘤1例[J]. 山东大学学报 (医学版), 2018, 56(9): 93-96. |
| [9] | 冯洒然,刘倩,王焱,李红,毕可红,朱传升. 系统性红斑狼疮伴发肝脾γδT细胞淋巴瘤1例并文献复习[J]. 山东大学学报 (医学版), 2018, 56(6): 87-90. |
| [10] | 李文生. “良性淋巴瘤”概念的提出及其存在的可能性[J]. 山东大学学报（医学版）, 2017, 55(3): 1-5. |
| [11] | 韩康康,崔立伟,彭程,薛玉文,肖伟. 多浆膜腔积液、Warburg效应——弥漫性大B细胞淋巴瘤1例报告并文献复习[J]. 山东大学学报（医学版）, 2016, 54(7): 80-87. |
| [12] | 郑敏,张岚. CAR-T抗肿瘤研究的现状及展望[J]. 山东大学学报（医学版）, 2016, 54(11): 1-6. |
| [13] | 姚月,张捷. 鼻型结外NK/T细胞淋巴瘤合并肺部感染1例[J]. 山东大学学报（医学版）, 2016, 54(11): 87-89. |
| [14] | 李星宇, 梁婧, 李岩. 血管内皮抑素协同肿瘤特异性DC-T细胞的抗肿瘤效应[J]. 山东大学学报（医学版）, 2015, 53(7): 19-23. |
| [15] | 高峰, 康白, 杨洪鸣, 赵廷坤, 曲梅花, 王金红. 皮肤T细胞淋巴瘤相关抗原5在肿瘤细胞株中的表达[J]. 山东大学学报（医学版）, 2015, 53(3): 41-45. |
|
||
